NCT04247256 2022-03-02A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRIScandion Oncology A/SPhase 1/2 Unknown35 enrolled